Okra

Okra (Abelmoschus esculentus): A Comprehensive Reference

1. Identity: Botanical Classification, Nomenclature, and Forms

Abelmoschus esculentus (L.) Moench, commonly known as okra or lady's finger, is an annual flowering plant belonging to the Malvaceae family. The genus name Abelmoschus derives from the Arabic abu-l-misk, meaning "father of musk," while the species epithet esculentus is Latin for "edible." The plant is also still found in older literature under the synonym Hibiscus esculentus L. Common names vary by region: it is called bhindi or bhendi in South Asia, bamya or bamia in the Middle East and parts of Europe, gumbo in the American South and Caribbean, quiabo in Brazil, and gombo in Francophone West Africa.

Okra is a remarkable botanical specimen due to its various uses; its roots, stem, leaves, fruits, and seeds are all valued for their nutritional, therapeutic, and industrial value. Okra is a multipurpose crop due to the varied use of its leaves, buds, flowers, pods, stems, and seeds.

The plant is available and used in a variety of preparations and forms:

• Fresh immature pods: the most common culinary form, consumed cooked, boiled, fried, or raw.
• Dried pod/fruit powder: produced by dehydrating the pods and grinding into powder, used in food products and supplement capsules.
• Seed powder or extract: concentrated for use in research formulations and supplements.
• Mucilage: the viscous, water-soluble polysaccharide fraction extracted from the fruit; studied for pharmaceutical and functional-food applications.
• Okra water: pods soaked overnight in water, a folk preparation used in several traditions.
• Capsules: encapsulated dried whole-fruit or extract, used in clinical trials.
• In ancient civilizations, the seed pods of okra were consumed cooked, dried, or ground into flour; leaves were also eaten cooked or raw; in many places, the seeds were toasted and ground for use as a coffee substitute.

2. History and Geographic Origin

Okra apparently originated in what geobotanists call the Abyssinian center of origin of cultivated plants, an area that includes present-day Ethiopia, the mountainous or plateau portion of Eritrea, and the eastern, higher part of the Anglo-Egyptian Sudan. The routes by which okra was taken from Ethiopia to North Africa, the eastern Mediterranean, Arabia, and India are by no means certain. Although it has been commonly cultivated in Egypt for many hundreds of years, no sign of it has been found in any ancient monuments or relics. Since the Spanish Moors and the Egyptians of the 12th and 13th centuries used an Arab word for okra, it probably was taken into Egypt by the Muslims from the East who conquered Egypt in the 7th century.

One of the earliest written accounts is by Abu al-Abbas al-Nabati, who visited Ayyubid Egypt in 1216 and described the plant under cultivation by the locals who ate the tender young pods with meal. From the Upper Nile, okra spread throughout North Africa and then to the Mediterranean, Asia, India, and the Caribbean.

The plant was introduced to the Americas by ships plying the Atlantic slave trade by 1658, when its presence was recorded in Brazil. It was further documented in Suriname in 1686. Okra may have been introduced to southeastern North America from Africa in the early 18th century. Some of the most notable crops brought by enslaved people from West African nations include okra, rice, yams, black-eyed peas, and kidney and lima beans. These starch staples were central to African diets, and seeds of these plants were cultivated in North America, becoming incorporated into the everyday diet of enslaved populations and afterward becoming main components of Southern cuisine.

In Louisiana, the Créoles learned from enslaved people the use of okra (gumbo) to thicken soups, and it is now an essential ingredient in Créole Gumbo.

3. Traditional and Ethnomedicinal Uses

Okra is a native plant in Africa as well as a traditional medicine in Africa and India for treating different diseases and conditions. Traditional use spans several major world regions, with preparations varying considerably depending on culture and available plant part.

Africa and the Middle East

Okra is commonly used in cooking but also in traditional medicine in the treatment of worms, dysentery, inflammation, and irritation of the stomach, intestines, and kidneys. Okra has long been used in traditional medicine due to its therapeutic potential in the Middle East, Far East, and Turkey.

Turkish Traditional Medicine

Okra, Abelmoschus esculentus (L.) (Malvaceae), is a medicinal plant widely used in Turkish traditional medicine for the treatment of various diseases such as ulcers and gastritis.

Traditional Chinese Medicine

In traditional medicine, okra is considered to exhibit antispasmodic, emollient poultice, diuretic, demulcent, laxative, cordial, and anticancer effects. Traditional Chinese medicine attributed cooling properties to the plant and used it in preparations intended to support digestion and reduce internal inflammation.

South Asia

In Ayurvedic and South Asian folk medicine, okra has found medical application as a plasma replacement or blood volume expander and is also useful in genitourinary disorders, spermatorrhoea, as an antioxidant, anticancer remedy, and in chronic dysentery.

Topical Applications

Medicinally, leaves of Abelmoschus esculentus were mashed to create a clay-type substance to apply to inflamed areas on the body. In traditional medicine, okra is believed to show diuretic, antispasmodic, demulcent and emollient poultice, cordial, laxative and anticancer effects.

4. Phytochemistry: Key Constituents and Active Compounds

Okra contains many vitamins, minerals, proteins and carbohydrates in addition to flavonoids, terpenes, phenolic compounds and sterols. Okra is a high-value crop because it represents a source of nutrients that are important to human health, including vitamins, potassium, calcium, carbohydrates, dietary fiber, and unsaturated fatty acids such as linolenic and oleic acids, as well as bioactive chemicals.

4.1 Mucilage and Polysaccharides

Okra mucilage is a highly viscous polysaccharide that is mostly composed of monosaccharides D-galactose, L-rhamnose, and galacturonic acid, as well as proteins and minerals. Almost all parts of okra contain high amounts of mucilage. Okra mucilage is generally an acidic polysaccharide composed of galacturonic acid, galactose, rhamnose, arabinose, and glucose. Approximately 35 percent of its polysaccharides contain uronic acid, and the predominant polysaccharide is rhamnogalacturonan.

4.2 Flavonoids and Polyphenols

Seven phenolic compounds were identified from extracted okra fruit, including quercetin, quercetin-3-O-glucoside (isoquercitrin), rutin, quercetin-3-O-gentiobioside, catechin, caffeic acid, and protocatechuic acid. Okra contains various polyphenolic and flavonoid components such as quercetin 3′-O-xylosyl glucoside, quercetin 3′-O-glucosyl glucoside, quercetin 3′-O-glucoside, quercetin 3′-O-(6″-O-malonyl)-glucoside, (−) epigallocatechin, rutin, hyperin, isoquercetin, hibifolin, and myricetin.

The contents of total polyphenols and total polysaccharides were 29.5% and 14.8% in okra seeds and 1.25% and 43.1% in okra skins, respectively. Total flavonoids, isoquercitrin and quercetin-3-O-gentiobiose (5.35%, 2.067%, and 2.741%, respectively) were only detected in okra seeds. In the fruit and its extracts, one can find the phenolic compounds catechin, isoquercitrin, protocatechuic acid, quercetin, quercetin-3-O-gentiobioside, and rutin. In okra mucilage, catechin, epigallocatechin gallate, and quercetin compounds have also been observed.

4.3 Dietary Fiber

The fiber composition of okra consists of 67.5% α-cellulose, 15.4% hemicellulose, 7.1% lignin, 3.4% pectic substance, 3.9% fatty and waxy matter, and 2.7% aqueous extract.

4.4 Other Phytochemicals

Phytochemical screening has revealed the presence of tannins, steroids, flavonoids, saponins, alkaloids, anthraquinones, phenols, terpenoids, cardiac glycosides, and cardenoids in okra. Okra is rich in bioactive compounds such as flavonoids, polysaccharides, polyphenols, caffeine, and pectin.

A substance frequently mentioned in okra seed extract is isoquercitrin, which has higher bioavailability than quercetin and displays a number of chemoprotective effects both in vitro and in vivo, against oxidative stress, cardiovascular disorders, diabetes, allergic reactions, and cancer.

5. Mechanisms of Action

Several mechanisms have been proposed based on preclinical and in-vitro research to explain the bioactivities attributed to okra's constituents. These have not all been confirmed in human trials.

5.1 Blood Glucose Regulation

Polyphenols inhibit the activities of α-glucosidase and α-amylase, mainly through hydrogen bonds and hydrophobic interaction. The antidiabetic effects of okra were also found to depend on the retardation of the rate of starch digestion and glucose absorption. These outcomes are attributed to the presence of secondary metabolites in okra fruit, including triterpenoids, phenolics, and the flavonoid quercetin, which functions as a hypoglycaemic agent. One of okra's main polysaccharides, AeP-P-1, activates signalling molecules in the PI3K/Akt pathway in liver tissue, restoring partial kidney and liver function in type 2 diabetic mice.

5.2 Lipid-Lowering Mechanisms

The okra fruit, mostly composed of the polysaccharide fraction, showed a significant ability to sequestrate cholic acid used as a model for bile acids. This effect can be valuable in the overall mechanisms of action because it can help to increase the fecal excretion of bile acid, thus contributing to the overall reduction of cholesterol. Leaf butanol extract was also found to induce the expression of both the LDLR (+3.1 ± 1.6-fold vs. control) and PCSK9. The lipid management effect of okra may be attributed to decreases in lipid peroxidation through binding with bile acid, prevention of bile acid reabsorption, and reducing liver cholesterol biosynthesis.

5.3 Anti-inflammatory Mechanisms

The evaluation of the potential anti-inflammatory effect revealed a significant action of leaf butanol extract with reduced mRNA levels of IL-1β (−28 ± 8% vs. control), IL-6 (−11 ± 1% vs. control), and TNF-α (−43 ± 8% vs. control). Recent evidence suggests that okra's bioactive compounds modulate inflammatory markers, including a reduction in pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, while enhancing anti-inflammatory mediators.

5.4 Antioxidant Mechanisms

Quercetin has free radical scavenging ability toward superoxide anions, peroxyl, and hydroxyl radicals. Antioxidant assays, including DPPH scavenging, ferric reducing antioxidant power (FRAP), and reducing power tests, showed okra seeds possess significant antioxidant effects. The antioxidant activity in okra and its active ingredients, especially isoquercitrin and quercetin-3-O-gentiobiose, not only contributed to its antidiabetic effect but was also found to be attributed to its hepatoprotective effect, antifatigue effect, vasoprotective effect, and neuroprotective effect.

5.5 Gastroprotective Mechanisms

Several studies found that pre-treatment with okra fruit extract, as aqueous extract with human gastric epithelia AGS cells, possessed an anti-adhesive effect on Helicobacter pylori. An in situ study stated that crude polysaccharides with a rhamnogalactan backbone have strong anti-adhesive activity towards H. pylori. This effect is due to its acid subfraction of polysaccharide (AF-III with a galacturonans backbone) and glycoprotein fraction.

5.6 Hepatoprotective Mechanisms

Quercetin and other polyphenols in okra protect the liver from inflammatory and oxidative stress, aiding in its normal function. Additionally, vitamin C in okra may chelate iron, reducing oxidative stress by limiting the availability of iron to catalyse reactive oxygen species formation, which is a major cause of liver inflammation.

6. Scientific Evidence by Area of Use

6.1 Glycemic Control and Diabetes

Overview and evidence strength: This is the most extensively studied area, with multiple randomized controlled trials (RCTs) and several systematic reviews and meta-analyses published through 2025. Evidence is moderately supportive, though heterogeneity across trials and methodological limitations prevent definitive conclusions.

Key RCTs:

• One study investigated the effect of okra whole fruit on blood glucose level of patients with type 2 diabetes mellitus with concomitant use of oral hypoglycemic agents. In this double-blind randomized clinical trial, 120 diabetic patients were assigned to an okra group (n = 60) and a control group (n = 60). The okra group received 1,000 mg of A. esculentus whole fruit capsules orally every 6 hours for 8 weeks. The control group received placebo capsule in the same manner. The levels of FBS (fasting blood sugar), BS (blood sugar), and HbA1c were significantly decreased in the okra group within the intervention compared to the control group (p < .05).
• Another clinical trial aimed to assess the efficacy and safety of the okra pod capsule as adjuvant treatment in controlling type 2 diabetes mellitus and to provide clinical trial-based evidence about its anti-inflammatory effects. The study demonstrated that adjunctive consumption of okra in type 2 diabetic patients at 1,000 mg three times a day for three months improves lipid profile, glycemic control, and chronic inflammation without any tangible adverse effects.

Systematic Reviews and Meta-Analyses:

• A meta-analysis of eight studies including 331 patients with pre-diabetes or type 2 diabetes found that okra treatment reduced levels of fasting blood glucose (MD = −14.63 mg/dL; 95% CI: −25.25, −4.00, p = 0.007; I² = 33%). Glycated haemoglobin, however, did not differ significantly between groups (MD = 0.01%; 95% CI: −0.51, 0.54, p = 0.96; I² = 23%).
• A separate meta-analysis of six eligible RCTs revealed that okra supplementation significantly reduced fasting blood glucose (FBG) (WMD: −21.72 mg/dL, 95% CI: −36.86 to −6.58, p = 0.005) and glycated hemoglobin (HbA1c) levels.
• A 2024 meta-analysis found that, compared to placebo, okra consumption remarkably decreased FBG (WMD: −32.56 mg/dL; 95% CI: −48.83, −16.28; p < 0.001), HbA1c (WMD: −0.48%; 95% CI: −0.81, −0.16; p = 0.004), TG (WMD: −13.16 mg/dL; p = 0.013), and TC (WMD: −9.70 mg/dL; p < 0.001) in adults. However, okra showed no notable impact on HOMA-IR, HDL-C, and LDL-C. The authors noted that more large-scale RCT studies are necessary to validate the beneficial effects of okra on adults due to the limited number of included RCTs.
• A 2026 systematic review and meta-analysis analyzing 14 randomized controlled trials published between 2020 and 2025, including a total of 836 participants, found that okra supplementation led to significant reductions in 2-hour postprandial glucose.

Limitations: Despite its promising therapeutic potential, research on the active compounds in okra and evaluating efficacy in clinical settings remains limited. Inconsistencies in study results may stem from factors such as dosage, intervention duration, and study design.

6.2 Lipid Profile and Dyslipidemia

Evidence strength: Emerging clinical evidence from a small number of RCTs, with pooled analyses showing modest but statistically significant effects on some lipid parameters.

Pooled evidence from a systematic review showed that supplementation with Abelmoschus esculentus reduces TC, TG, and LDL and increases HDL. The evidence from eight studies with nine treatment arms showed that Abelmoschus esculentus reduces total cholesterol (TC), SMD = −0.53 (95% CI: −1.00 to −0.07), p = 0.025, compared to placebo.

One meta-analysis concluded that okra decreased TC, LDL, FBG, and HbA1c levels in the intervention compared to the control group. A dose ≤3,000 mg/day caused a significant decrease in TG, TC, LDL, HbA1c, and a significant increase in HDL. However, the overall effect size showed that okra intake failed to change triglycerides, HDL, insulin, HOMA-IR, systolic blood pressure, diastolic blood pressure, body weight, and BMI significantly at all doses pooled together.

Preclinical studies have indicated the potential benefits of Abelmoschus esculentus and its active phytochemicals in addressing dyslipidemia in rodent models of diabetes. However, there is limited clinical evidence on lipid parameters.

6.3 Gastrointestinal Health and Gastric Ulcer Protection

Evidence strength: Primarily preclinical (animal) evidence with supporting mechanistic in-vitro data. No human clinical trials on gastroprotection have been identified in the literature reviewed.

In a rodent study, Wistar rats were treated with 500, 250, or 100 mg/kg okra; 20 mg/kg famotidine; and 75 mg/kg quercetin. Following a 60-minute period, all rats were given 1 mL of ethanol (80%) and then sacrificed one hour later. At 5,000 mg/kg, the extract produced no signs of toxicity. Okra 500, 250, and 100 mg/kg inhibited ulcer formation by 81.0%, 67.5%, and 67.0%, respectively.

The 500 mg/kg of body weight okra extract exerted a protective effect in aspirin-induced gastric ulcers by significantly reducing ulcer score, ulcer area, total acidity, and gastric volume, and significantly increasing gastric pH. A higher concentration of okra extract (500 mg/kg of body weight) showed almost similar results when compared to the reference drug omeprazole.

6.4 Antioxidant Activity

Evidence strength: Well established in vitro; confirmed in some animal models; human clinical data are limited but supportive of improved antioxidant status in diabetic populations receiving okra supplementation.

Studies confirm the presence of phenolic and flavonoid content in terms of gallic acid equivalent and quercetin equivalent in both mucilage and peel–seed mixtures. The presence of phenols and flavones demonstrates okra mucilage and peel–seed as a good source of antioxidants. Leaf ethyl acetate extract exerted significant antioxidant activity with IC50 comparable to ascorbic acid.

6.5 Anti-inflammatory Effects

Evidence strength: In-vitro and animal evidence is supportive. Limited human RCT data, primarily from diabetes trials, show reductions in inflammatory markers as a secondary endpoint.

A randomized double-blind placebo-controlled clinical trial demonstrated that adjunctive consumption of okra at 1,000 mg three times a day for three months in type 2 diabetic patients improves glycemic control and chronic inflammation without any tangible adverse effects. In vitro, evaluation of the potential anti-inflammatory effect revealed significant action of leaf butanol extract with reduced mRNA levels of IL-1β, IL-6, and TNF-α.

6.6 Anticancer Potential

Evidence strength: Preliminary; largely in-vitro and mechanistic data only. No human clinical trials on cancer endpoints have been identified.

Isoquercitrin, a substance frequently mentioned in okra seed extract, has higher bioavailability than quercetin and displays a number of chemoprotective effects both in vitro and in vivo. Isoquercitrin has shown inhibition of urinary bladder and pancreatic cancer progress, as well as colon cancer suppression. Despite these mentions, there is a paucity of reports regarding the anticancer effects of okra seeds specifically. Researchers have reviewed the role of active constituents such as pectin, epigallocatechin, and quercetin of Abelmoschus esculentus on tumor biology, with attention to its role in tumorigenesis and future research prospects in treating cancer.

6.7 Hepatoprotective Effects

Evidence strength: Primarily animal and in-vitro studies; limited human data as secondary outcomes in metabolic disease trials.

Variations in the chemical composition of okra result in different therapeutic activities including antidiabetic, hypolipidemic, antioxidant, antimicrobial, anticancer, wound healing, hepatoprotective, immunomodulator, neuroprotective, and gastroprotective activities in addition to cardioprotective activity. Quercetin and other polyphenols in okra protect the liver from inflammatory and oxidative stress, aiding in its normal function.

6.8 Neuroprotective Effects

Evidence strength: Preclinical only; no human clinical trial data identified.

The antioxidant activity in okra and its active ingredients, especially isoquercitrin and quercetin-3-O-gentiobiose, was found to contribute to its neuroprotective effect, including reducing the risk of developing Alzheimer's disease. In vitro and in vivo antidiabetic, antifatigue, antioxidant, antimicrobial, antihyperlipidemic, neuroprotective, and hepatoprotective impacts of okra have been described in the scientific literature.

6.9 Antifatigue Effects

Evidence strength: Animal studies only.

Weight-loaded swimming tests showed okra seeds possess significant anti-fatigue effects. The antioxidant activity in okra and its active ingredients was found to be attributed to its antifatigue effect.

7. Body Systems Associated with Okra

• Endocrine / Metabolic: Blood glucose regulation, insulin sensitization, HbA1c reduction — the primary area of human clinical evidence.
• Cardiovascular: Lipid-lowering effects on TC, LDL, TG; vasoprotective properties ascribed to polyphenols.
• Gastrointestinal: Gastroprotection against ulcer, anti-adhesive activity against H. pylori, laxative and demulcent effects via mucilage.
• Hepatic: Hepatoprotective effects through antioxidant and anti-inflammatory polyphenols.
• Neurological: Neuroprotective potential attributed to isoquercitrin and quercetin derivatives (preclinical only).
• Immune: Immunomodulatory effects reported in in-vitro studies.
• Musculoskeletal / Physical Performance: Antifatigue effects in animal models.

Potential beneficial effects are associated with okra and their components: cardioprotective, renal protective, neuroprotective, anticancer, analgesic, antiulcer, antibacterial, and antifatigue effects.

8. Dosage Forms and Doses Reported in Clinical Studies

In clinical studies reviewed, Abelmoschus esculentus was administered in various forms, including fruit powder, capsule, tea, or water immersion. The interventional dose ranged from 125 mg to 20,000 mg (20 g).

Specific doses reported in key trials include:

• 1,000 mg of whole fruit capsules orally every 6 hours for 8 weeks in one double-blind RCT in type 2 diabetes patients.
• 1,000 mg three times a day for three months in a double-blind placebo-controlled trial.
• 250 cc of okra extract solution daily for two weeks in a quasi-experimental study examining fasting blood sugar.
• 125 mg of dried okra extract daily for 10 weeks in a trial examining lipid profile.
• 20 g of dried Hibiscus esculentus fruit tea was used in one 2023 trial examining patients living with prediabetes.

No universally established therapeutic dose exists. A dose ≤3,000 mg/day appeared to cause significant decreases in TG, TC, LDL, and HbA1c, and a significant increase in HDL; however, more study is needed to determine the optimum dose and duration of intervention.

9. Safety Considerations and Drug Interactions

9.1 General Safety Profile

Human trials report an excellent safety profile, with no hepatotoxic, nephrotoxic, or cardiovascular adverse effects up to 3,000 mg/day for 12 weeks. The fruit and seeds are well tolerated in humans and other animals. At the animal level, at 5,000 mg/kg, okra extract produced no signs of toxicity.

9.2 Interaction with Metformin

An animal study demonstrated that concurrent administration of okra extract and metformin reduced metformin absorption and efficacy, indicating a potential drug–fiber interaction. While not yet confirmed in humans, clinicians should advise patients to separate dosing of okra-based supplements and oral antidiabetic medications.

9.3 Oxalate Content and Kidney Stones

Okra contains a high amount of oxalates, and calcium oxalate is the main culprit in developing kidney stones. Foods high in oxalate may increase the risk of kidney stones in people who have already had them.

9.4 Vitamin K Content and Anticoagulant Medications

Vitamin K aids in blood clotting, and okra's high vitamin K content may interact with blood-thinning medications such as warfarin.

9.5 Gastrointestinal Effects

Fructans are a type of carbohydrate found in okra, which may increase bowel problems in people with irritable bowel syndrome.

9.6 Evidence Gap

Although different in vivo and in vitro studies revealed that okra has an ability to overcome metabolic syndrome symptoms, the lack of clinical studies is notable. Despite its promising therapeutic potential, research on the active compounds in okra and evaluating efficacy in clinical settings remains limited.

References

• Ahmad N et al. (2025). An Overview of the Current Scientific Evidence on the Biological Properties of Abelmoschus esculentus (L.) Moench (Okra). Foods, 14(2), 177. PMC11764652
• Tahir A et al. (2023). A Review: Pharmacological Activity and Phytochemical Profile of Abelmoschus esculentus (2010–2022). RSC Advances. PMC10196740
• Gasparrini M et al. (2019). Abelmoschus esculentus (L.): Bioactive Components' Beneficial Properties—Focused on Antidiabetic Role—For Sustainable Health Applications. Molecules. PMC6337517
• Pereira A et al. (2021). Okra (Abelmoschus esculentus L.) as a Potential Functional Food Source of Mucilage and Bioactive Compounds with Technological Applications and Health Benefits. Frontiers in Plant Science. PMC8399980
• Mcomposed et al. (2021). Evaluation of in vitro antioxidant activity of okra mucilage and its antidiabetic and antihyperlipidemic effect in alloxan-induced diabetic mice. Food Science and Nutrition. PMC8645766
• Fan S et al. (2015). Antioxidant and Anti-Fatigue Constituents of Okra. Nutrients. PMC4632455
• Bahreini N et al. (2022). Anti-hyperglycemic effect of Abelmoschus esculentus (Okra) on patients with diabetes type 2: a randomized clinical trial. PubMed PMID 35434945
• Fan Y et al. (2025). The Impact of Okra Supplementation on Diabetes and Obesity Biomarkers in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of RCTs. Phytotherapy Research. PubMed PMID 40867089
• Mokgalaboni K et al. (2023). Okra ameliorates hyperglycaemia in pre-diabetic and type 2 diabetic patients: A systematic review and meta-analysis. PubMed PMID 37077817
• Tavakolizadeh M et al. (2023). Clinical efficacy and safety of okra in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Acta Diabetologica. PubMed PMID 37507536
• Khalili P et al. (2024). The cardiometabolic benefits of okra-based treatment in prediabetes and diabetes: a systematic review and meta-analysis. Frontiers in Nutrition. PubMed PMID 39726865
• Zhang X et al. (2024). The Effects of Okra Consumption on Glycemic Parameters and Lipid Profile in Adults: A Systematic Review and Meta-Analysis. Food Science & Nutrition.
• Abubakar AR et al. (2024). Effect of Abelmoschus esculentus L. (Okra) on Dyslipidemia: Systematic Review and Meta-Analysis of Clinical Studies. PMC11507881
• Panighel G et al. (2022). Investigating the in vitro mode of action of okra as hypocholesterolemic, anti-inflammatory, and antioxidant food. Biomedicine & Pharmacotherapy. PMC9352527
• Şahin K et al. (2018). In vivo anti-ulcerogenic effect of okra on ethanol-induced acute gastric mucosal lesions. PMC6130549
• Musa NH et al. (2020). Ethanolic extract of okra has a potential gastroprotective effect on acute gastric lesions in Sprague Dawley rats. PMC7723190
• Sánchez-Moreno C et al. (2019). The Effect of Okra Seed Extract on Human Cancer Cell Lines Delivered in Its Native Form and Loaded in Polymeric Micelles. PMC6855069
• Norouzi S et al. (2020). Effect of Abelmoschus esculentus (okra) on metabolic syndrome: A review. PubMed PMID 32222004
• Jafari A et al. (2026). Therapeutic potential of okra in dysglycaemia and metabolic dysfunction: A systematic review and meta-analysis. Experimental Physiology.
• Texas A&M AgriLife Extension. Okra, or "Gumbo," from Africa — Vegetable Travelers.
• New York Botanical Garden. Okra's Journey to the United States.
• Jafari A et al. (2025). Beneficial effects of okra on anthropometric measures, blood pressure, glycaemic control, lipid profile and liver function tests in RCTs: a GRADE-assessed systematic review. British Journal of Nutrition. Cambridge Core.